- Raw materials
- Central Nervous System Agents
- Huperzine A
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Huperzine A API Manufacturers & Suppliers
2 verified results
Commercial-scale Suppliers
Employees: 50+
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Huperzine A | CAS No: 102518-79-6 | GMP-certified suppliers
A medication that is investigated for Alzheimer's disease treatment, offering neuroprotective benefits as a central nervous system cholinesterase inhibitor with potential cognitive support.
Therapeutic categories
Primary indications
- Investigated for use/treatment in alzheimer's disease
Product Snapshot
- Huperzine A is an oral small molecule formulation
- It is primarily investigated for neurodegenerative conditions, notably Alzheimer's disease
- The compound has both approved and experimental regulatory status in various markets
Clinical Overview
Pharmacologically, huperzine A is classified within the quinolones and derivatives, compounds characterized by a quinoline structure with a ketone substituent. It functions primarily as an acetylcholinesterase inhibitor, a mechanism that enhances cholinergic neurotransmission by preventing the hydrolysis of acetylcholine in synaptic clefts. This mechanism is shared with licensed pharmaceuticals such as galantamine and donepezil, which are established treatments for the cognitive symptoms of Alzheimer’s disease. Clinical trials conducted in China have demonstrated that huperzine A exhibits similar efficacy levels to these approved agents and may exhibit a favorable side effect profile.
Regarding pharmacokinetics, detailed data on absorption, distribution, metabolism, and excretion (ADME) parameters remain limited in publicly available literature. However, preliminary studies suggest that huperzine A has good oral bioavailability and is capable of crossing the blood-brain barrier to exert central nervous system effects.
Safety considerations include monitoring for typical cholinergic adverse events such as nausea, dizziness, and gastrointestinal disturbances. Long-term safety data are still under investigation, and regulatory approval status varies by region, with huperzine A recognized as an experimental or approved agent depending on local regulatory frameworks.
For formulation scientists and sourcing professionals, the quality and purity of huperzine A API are critical due to its narrow therapeutic index and sensitivity to degradation. Procurement should prioritize suppliers who provide comprehensive analytical documentation, including identity, potency, residual solvents, and impurity profiles, adhering to pharmacopeial standards or equivalent specifications to support downstream manufacturing and regulatory compliance.
Identification & chemistry
| Generic name | Huperzine A |
|---|---|
| Molecule type | Small molecule |
| CAS | 102518-79-6 |
| UNII | 0111871I23 |
| DrugBank ID | DB04864 |
Pharmacology
| Summary | Huperzine A is a natural alkaloid that functions as a reversible acetylcholinesterase inhibitor, targeting the enzyme responsible for the breakdown of acetylcholine. It is under investigation for therapeutic use in Alzheimer's disease, aiming to enhance cholinergic neurotransmission. Pharmacodynamically, it exhibits similar inhibitory effects on acetylcholinesterase as established Alzheimer's treatments like donepezil and galantamine. |
|---|---|
| Mechanism of action | Huperzine A has been found to be an inhibitor of the enzyme acetylcholinesterase. This is the same mechanism of action of pharmaceutical drugs such as [galantamine] and [donepezil] used to treat Alzheimer's disease. |
| Pharmacodynamics | Huperzine A is an alkaloid derived from <i>Huperzia serrata</i> (which is available as an herbal product in the US). It is under investigation as an acetylcholinesterase inhibitor. Clinical trials in China have shown that huperzine A is comparably effective to the drugs currently on the market, and may even be somewhat safer in terms of side effects. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Acetylcholinesterase | Humans | inhibitor |
Formulation & handling
- Huperzine A is a small molecule with moderate water solubility, suitable for oral formulations.
- Its quinolone structure suggests chemical stability under standard handling but may require protection from strong oxidizing agents.
- Formulation should consider low LogP for absorption optimization, with minimal food interaction expected.
Regulatory status
Huperzine A is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
Huperzine A API manufacturers & distributors
Compare qualified Huperzine A API suppliers worldwide. We currently have 2 companies offering Huperzine A API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Ningbo G-H Pharma | Producer | China | China | CoA, USDMF | 3 products |
| Sinoway industrial Co.,Lt... | Distributor | China | China | CEP, CoA, GMP, ISO9001, MSDS, USDMF | 757 products |
When sending a request, specify which Huperzine A API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Huperzine A API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
